TD

Teladoc Health, Inc.

TDOCHealthcareNASDAQ

Health Information Services

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.53B
-1.5% YoY
Net Income
-$200.3M
+80.0% YoY
EBITDA
$160.6M
+127.4% YoY
Free Cash Flow
$191.0M

Scan Results

Daily timeframe
DateIndicatorDetails
Oct 15▲ MACD Positive CrossoverHistogram +0.0432, positive momentum
Oct 14▲ MACD Positive CrossoverHistogram +0.0428, positive momentum
About Teladoc Health, Inc.

Teladoc Health, Inc. provides virtual healthcare services worldwide. The company carries a $1.15B market cap, placing it firmly in the small-cap category. It operates through Teladoc Health Integrated Care and BetterHelp segments.

Where TDOC stands vs its 150-day and 200-day moving averages

As of the October 15, 2026 close, TDOC finished 14.05% below its 150-day moving average ($6.76) and 10.75% below its 200-day moving average ($6.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is TDOC overbought or oversold?

At the October 15, 2026 close, TDOC's RSI(14) was 41.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.15B
Fwd P/E-8.77
EPS$-0.99
Beta2.14
52W Change-29.6%
Dividend Yield0.00%
ROE-13.0%
Analysis

Teladoc Health, Inc. carries $1.04B in total debt against $774.3M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $191.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -13.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $2.41B (2022) to $2.53B (2025).

With a beta above 1.5, TDOC tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. No single metric tells the full story. Reviewing TDOC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms